FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167243018> ?p ?o ?g. }

• W2167243018 abstract "Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of the limits imposed on administered activity levels by radiation damage to normal tissues. The goal of this study was to evaluate the dosimetric advantages of adding (131)I meta-iodobenzylguanidine ((131)I-MIBG) to (90)Y DOTA Phe1-Tyr3-octreotide ((90)Y-DOTATOC) in patients with advanced stage midgut NETs.Ten patients were imaged simultaneously with (131)I-MIBG and (111)In-pentetreotide (as a surrogate for (90)Y-DOTATOC) on days 1, 2, and 3 post-administration. Blood samples were obtained at the same time points. Using dosimetry measures from this data and our previously published methodology for calculating optimal combined administered activity levels for therapy, we determined the amount of (131)I-MIBG that could be added to (90)Y-DOTATOC without exceeding normal organ dose limits (marrow and kidneys) along with the expected increase in associated tumor dose, if any.We found that a median value of 34.6 GBq of (131)I-MIBG could be safely added to (90)Y-DOTATOC (delivered over multiple cycles) by reducing the maximum total deliverable (90)Y-DOTATOC by a median value of 24.5%. Taking this treatment approach, we found that there would be a median increase in deliverable tumor dose of 4,046 cGy in six of the ten subjects. Of note, there were a small number of metastases that were positive for only one or the other of these radiopharmaceuticals within the same subject.We conclude that approximately half of the patients with midgut NETs that are eligible for PRRT could reasonably be expected to benefit from the addition of (131)I-MIBG to (90)Y-DOTATOC." @default.
• W2167243018 created "2016-06-24" @default.
• W2167243018 creator A5005755070 @default.
• W2167243018 creator A5019440539 @default.
• W2167243018 creator A5027597209 @default.
• W2167243018 creator A5037158035 @default.
• W2167243018 creator A5039341909 @default.
• W2167243018 creator A5053861567 @default.
• W2167243018 creator A5067451507 @default.
• W2167243018 date "2014-09-10" @default.
• W2167243018 modified "2023-10-16" @default.
• W2167243018 title "Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors" @default.
• W2167243018 cites W1526500864 @default.
• W2167243018 cites W1542976343 @default.
• W2167243018 cites W1829445575 @default.
• W2167243018 cites W1933764379 @default.
• W2167243018 cites W1944076654 @default.
• W2167243018 cites W1985381213 @default.
• W2167243018 cites W2005674134 @default.
• W2167243018 cites W2005782011 @default.
• W2167243018 cites W2006821285 @default.
• W2167243018 cites W2008565167 @default.
• W2167243018 cites W2009629472 @default.
• W2167243018 cites W2010247282 @default.
• W2167243018 cites W2024786905 @default.
• W2167243018 cites W2033305913 @default.
• W2167243018 cites W2036154071 @default.
• W2167243018 cites W2036524999 @default.
• W2167243018 cites W2041147239 @default.
• W2167243018 cites W2055853082 @default.
• W2167243018 cites W2064522544 @default.
• W2167243018 cites W2065387828 @default.
• W2167243018 cites W2075600713 @default.
• W2167243018 cites W2092047830 @default.
• W2167243018 cites W2092706522 @default.
• W2167243018 cites W2107569469 @default.
• W2167243018 cites W2108209753 @default.
• W2167243018 cites W2122334532 @default.
• W2167243018 cites W2125398839 @default.
• W2167243018 cites W2126557384 @default.
• W2167243018 cites W2128669850 @default.
• W2167243018 cites W2143973920 @default.
• W2167243018 cites W2145110674 @default.
• W2167243018 cites W2148394335 @default.
• W2167243018 cites W2148881212 @default.
• W2167243018 cites W2154245012 @default.
• W2167243018 cites W2158466122 @default.
• W2167243018 cites W2177207346 @default.
• W2167243018 cites W2226900762 @default.
• W2167243018 cites W2320378887 @default.
• W2167243018 cites W2334698480 @default.
• W2167243018 doi "https://doi.org/10.1186/s13550-014-0038-2" @default.
• W2167243018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4452658" @default.
• W2167243018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26116109" @default.
• W2167243018 hasPublicationYear "2014" @default.
• W2167243018 type Work @default.
• W2167243018 sameAs 2167243018 @default.
• W2167243018 citedByCount "12" @default.
• W2167243018 countsByYear W21672430182016 @default.
• W2167243018 countsByYear W21672430182017 @default.
• W2167243018 countsByYear W21672430182018 @default.
• W2167243018 countsByYear W21672430182020 @default.
• W2167243018 countsByYear W21672430182021 @default.
• W2167243018 countsByYear W21672430182022 @default.
• W2167243018 countsByYear W21672430182023 @default.
• W2167243018 crossrefType "journal-article" @default.
• W2167243018 hasAuthorship W2167243018A5005755070 @default.
• W2167243018 hasAuthorship W2167243018A5019440539 @default.
• W2167243018 hasAuthorship W2167243018A5027597209 @default.
• W2167243018 hasAuthorship W2167243018A5037158035 @default.
• W2167243018 hasAuthorship W2167243018A5039341909 @default.
• W2167243018 hasAuthorship W2167243018A5053861567 @default.
• W2167243018 hasAuthorship W2167243018A5067451507 @default.
• W2167243018 hasBestOaLocation W21672430181 @default.
• W2167243018 hasConcept C126322002 @default.
• W2167243018 hasConcept C126838900 @default.
• W2167243018 hasConcept C146357865 @default.
• W2167243018 hasConcept C151730666 @default.
• W2167243018 hasConcept C162324750 @default.
• W2167243018 hasConcept C187736073 @default.
• W2167243018 hasConcept C21883318 @default.
• W2167243018 hasConcept C2776297358 @default.
• W2167243018 hasConcept C2779066768 @default.
• W2167243018 hasConcept C2781025020 @default.
• W2167243018 hasConcept C2989005 @default.
• W2167243018 hasConcept C2993559085 @default.
• W2167243018 hasConcept C509974204 @default.
• W2167243018 hasConcept C71924100 @default.
• W2167243018 hasConcept C75088862 @default.
• W2167243018 hasConcept C86803240 @default.
• W2167243018 hasConceptScore W2167243018C126322002 @default.
• W2167243018 hasConceptScore W2167243018C126838900 @default.
• W2167243018 hasConceptScore W2167243018C146357865 @default.
• W2167243018 hasConceptScore W2167243018C151730666 @default.
• W2167243018 hasConceptScore W2167243018C162324750 @default.
• W2167243018 hasConceptScore W2167243018C187736073 @default.
• W2167243018 hasConceptScore W2167243018C21883318 @default.
• W2167243018 hasConceptScore W2167243018C2776297358 @default.
• W2167243018 hasConceptScore W2167243018C2779066768 @default.
• W2167243018 hasConceptScore W2167243018C2781025020 @default.

• next